{"issuance_frequency":"","notes_translated":{"fr":"Annual recommendations on the use of influenza vaccine in Canada are developed by the NACI Influenza Working Group (IWG) for consideration by NACI. Recommendations are developed based on a review of a variety of issues, which can include: the burden of influenza illness and the target populations for vaccination; efficacy, effectiveness, immunogenicity, and safety of influenza vaccines; vaccine schedules; and other aspects of influenza immunization. In addition, PHAC has expanded the mandate of NACI to include the consideration of programmatic factors in developing their recommendations to facilitate timely decision-making for publicly funded vaccine programs at provincial and territorial levels. These programmatic factors include economics, ethics, equity, feasibility, and acceptability.","en":"Annual recommendations on the use of influenza vaccine in Canada are developed by the NACI Influenza Working Group (IWG) for consideration by NACI. Recommendations are developed based on a review of a variety of issues, which can include: the burden of influenza illness and the target populations for vaccination; efficacy, effectiveness, immunogenicity, and safety of influenza vaccines; vaccine schedules; and other aspects of influenza immunization. In addition, PHAC has expanded the mandate of NACI to include the consideration of programmatic factors in developing their recommendations to facilitate timely decision-making for publicly funded vaccine programs at provincial and territorial levels. These programmatic factors include economics, ethics, equity, feasibility, and acceptability."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"unknown","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"d5e55d4d-3f3d-4561-b793-f7ed3e1acd83","metadata_created":"2021-06-29T06:31:04.100000","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-10-23T19:00:52.175662","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-06-28","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["vaccin","grippe","Comité","consultatif","national","l’immunisation","Une déclaration","d'un comité consultatif","DCC","CCNI","ARN","Acide","ribonucléique","CDC","Centers for Disease Control","Prevention","DIN","Numéro","d'identification","médicament","ECR","Essai","contrôlé","randomisé","ÉI","Évènements","indésirables","ESSI","EP","Efficacité","potentielle","réelle","Effet","secondaire","suivant","GCI","Guide","canadien","HAART","HA","Hémagglutinine","Traitement","antirétroviral","hautement","actif","IC","Intervalle","confiance","Ig","Immunoglobuline","IM","Intramusculaire","IMC","Indice","masse","corporelle","IMPACT","Programme","canadien","surveillanc","active","de","MGT","Moyenne","géométrique","titres","NA","Neuraminidase","OMS","Organisation","mondiale","Santé","PS","Professionnel","santé","RMGT","Rapport","de la moyenne","géométrique","titres","RRO","Vaccin contre","rougeole","rubéole","oreillons","SCSESSI","Système","canadien","surveillance","SGB","Syndrome","Guillain-Barré","SOR","Syndrome","oculo-respiratoire","TNDN","Troubles","neurologiques","développement","neurologique","TS","Travailleur","santé","UFF","Unité","foyers","fluorescents","VII","Vaccin","inactivé","contre","l'influenza","VII3","Vaccin trivalent","inactivé","contreVII3-Adj","Vaccin","inactivé","contre","adjuvant","VII3-SD","Vaccin","trivalent","inactivé","contre","dose","standard","VII3-HD","trivalent","contre","haute","VII4","quadrivalent","VII4-SD","VIH","Virus","immunodéficience","humaine","VRZ","recombinant","zona","VVAI","vivant","atténué","VVAI3","atténué","VVAI4"],"en":["Influenza","vaccine","National","Advisory","Committee","Immunization","Adverse","event","AEFI","CAEFISS","Canadian","Adverse","Events","Following","Immunization","Surveillance","System","CI","Confidence","interval","CIG","Canadian","Guide","DIN","Drug","Identification","Number","FFU","Fluorescent","focus","units","GBS","Guillain-Barré","syndrome","GMT","Geometric","mean","titre","GMTR","Geometric","ratio","HA","Hemagglutinin","HAART","Highly","active","antiretroviral","therapy","HCW","Health","care","worker","HIV","Human","immunodeficiency","virus","Ig","Immunoglobulin","IIV","Inactivated","IIV3","Trivalent","inactivated","IIV3-Adj","Adjuvanted","IIV3-HD","High-dose","trivalent inactivated","IIV3-SD","Standard-dose","IIV4","Quadrivalent","inactivated","IIV4-SD","Standard-dose","ILI","Influenza-like","illness","IM","Intramuscular","Immunization","Monitorin","Program","Active","LAIV","Live","attenuated","LAIV3","Trivalent","live","attenuated","LAIV4","Quadrivalent","MMR","Measles","mumps","rubella","NA","Neuraminidase","NACI ORS","Oculorespiratory","syndrome","RCT","Randomized","controlled","trial","RNA","Ribonucleic acid","RZV","Recombinant","zoster","vaccine","SAE","Serious","adverse","event","VE","Vaccine","effectiveness","WHO","World Health","Organization","Advisory","Committee","Statement","ACS","IMPACT"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Chapitre sur la grippe du Guide canadien d’immunisation et Déclaration sur la vaccination antigrippale pour la saison 2021-2022","en":"Canadian Immunization Guide Chapter on influenza and statement on seasonal influenza vaccine for 2021–2022 "},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"d5e55d4d-3f3d-4561-b793-f7ed3e1acd83","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"16b59e27-b4c8-4ecd-ab7e-fb1893fd15d0","related_relationship":"","name_translated":{"fr":"Chapitre sur la grippe du Guide canadien d’immunisation et Déclaration sur la vaccination antigrippale pour la saison 2021-2022","en":"Canadian Immunization Guide Chapter on influenza and statement on seasonal influenza vaccine for 2021–2022 "},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Canadian Immunization Guide Chapter on influenza and statement on seasonal influenza vaccine for 2021–2022 ","language":["en"],"created":"2021-06-29T06:31:04.249815","url":"https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2021-2022.html","last_modified":null,"position":0,"revision_id":"85141425-0f82-40d6-8268-986c04f8410b","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"d5e55d4d-3f3d-4561-b793-f7ed3e1acd83","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"bc7bfb1b-03f4-4dd9-b016-82a6e997d004","related_relationship":"","name_translated":{"fr":"Chapitre sur la grippe du Guide canadien d’immunisation et Déclaration sur la vaccination antigrippale pour la saison 2021-2022","en":"Canadian Immunization Guide Chapter on influenza and statement on seasonal influenza vaccine for 2021–2022 "},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Canadian Immunization Guide Chapter on influenza and statement on seasonal influenza vaccine for 2021–2022 ","language":["fr"],"created":"2021-06-29T06:31:04.249847","url":"https://www.canada.ca/fr/sante-publique/services/publications/vaccins-immunisation/guide-canadien-immunisation-declaration-vaccination-antigrippale-2021-2022.html","last_modified":null,"position":1,"revision_id":"85141425-0f82-40d6-8268-986c04f8410b","resource_type":"website"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Agence de la santé publique du Canada","en":"Public Health Agency of Canada"},"date_published":"2021-05-31 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:57.068700","title":"Public Health Agency of Canada | Agence de la santé publique du Canada","name":"phac-aspc","is_organization":true,"state":"active","image_url":"","revision_id":"96161da6-edc7-4d1d-99e0-baac9df7b3b9","type":"organization","id":"1C71053B-AA64-4646-956B-41631C396018","approval_status":"approved"},"name":"d5e55d4d-3f3d-4561-b793-f7ed3e1acd83","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"Annual recommendations on the use of influenza vaccine in Canada are developed by the NACI Influenza Working Group (IWG) for consideration by NACI. Recommendations are developed based on a review of a variety of issues, which can include: the burden of influenza illness and the target populations for vaccination; efficacy, effectiveness, immunogenicity, and safety of influenza vaccines; vaccine schedules; and other aspects of influenza immunization. In addition, PHAC has expanded the mandate of NACI to include the consideration of programmatic factors in developing their recommendations to facilitate timely decision-making for publicly funded vaccine programs at provincial and territorial levels. These programmatic factors include economics, ethics, equity, feasibility, and acceptability.","owner_org":"1C71053B-AA64-4646-956B-41631C396018","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Canadian Immunization Guide Chapter on influenza and statement on seasonal influenza vaccine for 2021–2022 ","revision_id":"85141425-0f82-40d6-8268-986c04f8410b"}